Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
04
09
2020
received:
24
01
2020
accepted:
22
09
2020
pubmed:
29
9
2020
medline:
15
2
2022
entrez:
28
9
2020
Statut:
ppublish
Résumé
To describe the baseline characteristics of patients with positivity for antiphospholipid antibodies (aPLs) who were enrolled in an international registry, the Antiphospholipid Syndrome (APS) Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository, overall and by clinical and laboratory subtypes. The APS ACTION registry includes adults who persistently had positivity for aPLs. We evaluated baseline sociodemographic and aPL-related (APS classification criteria and "non-criteria") characteristics of patients overall and in subgroups (aPL-positive without APS, APS overall, thrombotic APS only, obstetric APS only, and both thrombotic APS/obstetric APS). We assessed baseline characteristics of patients tested for the presence of three aPLs (lupus anticoagulant [LAC] test, anticardiolipin antibody [aCL], and anti-β The 804 aPL-positive patients assessed in the present study had a mean age of 45 ± 13 years, were 74% female, and 68% White; additionally, 36% had other systemic autoimmune diseases. Of these 804 aPL-positive patients, 80% were classified as having APS (with 55% having thrombotic APS, 9% obstetric APS, and 15% thrombotic APS/obstetric APS). In the overall cohort, 71% had vascular thrombosis, 50% with a history of pregnancy had obstetric morbidity, and 56% had experienced at least one non-criteria manifestation. Among those with three aPLs tested (n = 660), 42% were triple aPL-positive. While single-, double-, and triple aPL-positive subgroups had similar frequencies of vascular, obstetric, and non-criteria events, these events were lowest in the single aPL subgroup, which consisted of aCLs or anti-β Our study demonstrates the heterogeneity of aPL-related clinical manifestations and laboratory profiles in a multicenter international cohort. Within single aPL positivity, LAC may be a major contributor to clinical events. Future prospective analyses, using standardized core laboratory aPL tests, will help clarify aPL risk profiles and improve risk stratification.
Substances chimiques
Antibodies, Antiphospholipid
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-335Subventions
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : Canada Research Chairs
Organisme : NIH HHS
ID : R01-AR069572
Pays : United States
Organisme : Rheumatology Research Foundation
Organisme : Clinical and Translational Science Center at Weill Cornell Medical College
ID : UL1-TR000457
Informations de copyright
© 2020, American College of Rheumatology.
Références
Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
Barbhaiya M, Andrade D, Bertolaccini M, Erkan D. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights. Cham: Springer International Publishing; 2017. p. 267-76.
Levine J, Branch, DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
Cervera R, Serrano R, Pons-Estel G, Ceberio-Hualde L, Shoenfeld Y, Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2014;74:1011-8.
Abdel-Wahab N, Lopez-Olivio M, Pinto-Patarroyo G, Suarez-Almazor M. Systematic review of case reports of antiphospholipid syndrome following infection. Lupus 2016;25:1520-31.
Reinstein E, Shoenfeld Y. Antiphospholipid syndrome and cancer. Clin Rev Allergy Immunol 2007;32:184-7.
Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147-52.
Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-42.
Yelnik C, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 2017;26:163-9.
Cervera R, Piette J, Font J, Khamashta M, Shoenfeld Y, Camps M, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016;3:75-84.
Duarte-García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019;71:1545-52.
Pengo V, Tripodi A, Reber G, Rand J, Ortel T, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737-40.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Infor 2009;42.
Asherson R, Cervera R, de Groot P, Erkan D, Boffa M-C, Piette JC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530-4.
Unlu O, Domingues V, de Jesús GR, Zuily S, Espinosa G, Cervera R, et al. Definition and epidemiology of antiphospholipid syndrome. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights. Cham: Springer International Publishing; 2017. p. 147-69.
Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci U S A 1991;88:3069-73.
Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 1995;74:1361-7.
Zuily S, Wahl D. Pulmonary hypertension in antiphospholipid syndrome. Curr Rheumatol Rep 2015;17:478.
Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006;166:2278-84.
Abreu MM, Danowski A, Wahl DG, Amigo MC, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015;14:401-14.
Zuily S, Clerc-Urmes I, Wahl D, Erkan D. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Cluster Analysis for Identification of Different Clinical Phenotypes Among Antiphospholipid Antibody-Positive Patients. Lupus 2016;25:74-5.
Zuily S, Clerc-Urmes I, Chighizola C, Baumann C, Wahl D, Meroni P, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository cluster analysis for the identification of different clinical phenotypes among antiphospholipid antibody-positive female patients with a history of pregnancy. Lupus 2016;25:61.
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-21.
Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco P, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996;100:530-6.
Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, et al. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009;123:444-51.
Zuily S, de Laat B, Mohamed S, Kelchtermans H, Shums Z, Albesa R, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 2015;54:2071-5.
Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus 2014;23:1468-76.
Wahl DG, Guillemin F, Maistre E de, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus 1997;6:467-73.
Zuily S, Regnault V, Selton-Suty C, Eschwege V, Bruntz J-F, Bode-Dotto E, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation 2011;124:215-24.
Domingues V, Magder LS, Petri M. Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med 2016;3:e000107.
Lockshin M, Kim M, Laskin C, Guerra M, Branch D, Merrill J, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012;64:2311-8.
Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Autoimmunity Reviews 2014;13:685-696.
Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4380-4.
Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017;65:17-24.
Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013;65:464-71.
Elazary AS, Klahr P, Hershko A, Dranitzki Z, Rubinow A, Naparstek Y. Rituximab induces resolution of recurrent diffuse alveolar hemorrhage in a patient with primary antiphospholipid antibody syndrome. Lupus 2011;21:438-40.
Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014;14:459-65.
Zapantis E, Furie R, Horowitz D. Response to eculizumab in the antiphospholipid antibody syndrome. Ann Rheum Dis 2015;74:341.
Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.
Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9.
Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408-13.
Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-87.
Munoz-Rodriguez FJ, Font J, Cervera R, Reverter JC, Tassies D, Espinosa G, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum 1999;29:182-90.
Zuo Y, Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: where do we stand in 2018? Curr Rheumatol Rep 2018;20:66.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296.
Ugolini-Lopes M, Rosa R, Nascimento I, R de Jesus G, Levy R, Erkan D, et al, on behalf of APS ACTION registry. APS ACTION clinical database and repository analysis: primary antiphospholipid syndrome in Brazil versus other regions of the world [abstract]. Lupus 2016;25 Supp 1S:76.
Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012;10:2512-8.
Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, et al. Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782-7.
Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal clinical database and repository. Arthritis Care Res (Hoboken) 2019;71:134-41.